Volume 7.09 | Mar 12

Cord Blood News 7.09 March 12, 2015
Cord Blood News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook   CBN on Twitter
Mild Heat Treatment Primes Human CD34+ Cord Blood Cells for Migration towards SDF-1α and Enhances Engraftment in an NSG Mouse Model
Researchers hypothesized that short-term exposure of CD34+ cord blood cells to 39.5 °C would enhance their response to SDF-1, by increasing lipid raft aggregation and CXCR4 expression, thus leading to enhanced engraftment. [Stem Cells] Abstract
Request a Sample: ReproTeSR™
PUBLICATIONS (Ranked by impact factor of the journal)
Mesenchymal Stem Cell Therapy Alleviates Interstitial Cystitis by Activating Wnt Signaling Pathway
Researchers evaluated the therapeutic potency of using human umbilical cord-blood derived mesenchymal stem cells to treat interstitial cystitis in a rat model and investigated its responsible molecular mechanism. [Stem Cells Dev] Abstract

Human Placenta-Derived CD146-Positive Mesenchymal Stromal Cells Display a Distinct Osteogenic Differentiation Potential
Scientists investigated if expression of CD146 on mesenchymal stromal cells (MSCs) from placenta correlates with a similar osteogenic differentiation potential. The MSCs were isolated specifically from the endometrial and fetal parts of human term placenta and expanded in separate cultures, and compared to MSCs from bone marrow as controls. [Stem Cells Dev] Abstract

Effect of HSA Coated Iron Oxide Labeling on Human Umbilical Cord Derived Mesenchymal Stem Cells
Researchers analyzed the efficacy of human serum albumin (HSA) coated iron oxide nanoparticles on the differentiation of human umbilical cord derived mesenchymal stem cells. [Nanotechnology] Abstract

Three-Dimensional Spheroid Culture of Human Umbilical Cord Mesenchymal Stem Cells Promotes Cell Yield and Stemness Maintenance
Investigators established a novel three-dimensional (3D) system for the culture of human umbilical cord mesenchymal stem cells within a real 3D microenvironment but with no digestion or passaging. [Cell Tissue Res] Abstract

Combination Therapy with Human Umbilical Cord Mesenchymal Stem Cells and Angiotensin-Converting Enzyme 2 Is Superior for the Treatment of Acute Lung Ischemia-Reperfusion Injury in Rats
Researchers aimed to explore a more effective treatment method by combining human umbilical cord mesenchymal stem cells and angiotensin-converting enzyme 2 for acute lung ischemia-reperfusion injury. [Cell Biochem Funct] Abstract

Stem Cells Derived from Human First-Trimester Umbilical Cord Have the Potential to Differentiate into Oocyte-Like Cells In Vitro
Scientists investigated whether stem cells derived from human first-trimester umbilical cord (hFTUCs) are able to differentiate into germ cells. The hFTUCs were first isolated, expanded and then cultured in differentiation medium containing human follicular fluid, follicle-stimulating hormone/luteinizing hormone and estradiol for 24 days. [Int J Mol Med] Abstract | Download Full Article

Effects of Hypoxia on Proliferation of Human Cord Blood-Derived Mesenchymal Stem Cells
Researchers found that hypoxia, in part via hypoxia-inducible factor-1α, improved the proliferation efficiency, and prevented senescence of human umbilical cord blood-derived mesenchymal stem cells without altering their morphology and surface markers. [Cytotechnology] Abstract

Hematopoietic Course for Cord Blood - Learn More and Register
Wharton’s Jelly Derived Mesenchymal Stromal Cells: Biological Properties, Induction of Neuronal Phenotype and Current Applications in Neurodegeneration Research
The authors provide an overview of the main biological properties of Wharton’s jelly-derived mesenchymal stem cells. Moreover, the potential application of these cells for the treatment of some known dysfunctions in the central and peripheral nervous system are discussed. [Acta Histochem] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.
Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for Captisol-Enabled™ (Propylene Glycol-Free) Melphalan
Spectrum Pharmaceuticals announced that its New Drug Application (NDA) for Captisol-Enabled Melphalan, has been accepted by the U.S. Food and Drug Administration (FDA). Spectrum is seeking FDA approval for its use as a high-dose conditioning treatment prior to autologous hematopoietic (progenitor) stem cell transplantation in patients with multiple myeloma, an orphan drug designation. [Spectrum Pharmaceuticals] Press Release

AOP Orphan Pharmaceuticals Announces Progress of Pivotal Phase III Trial PROUD-PV Applying Ropeginterferon Alfa 2b, a Novel, Long-Acting, Mono-Pegylated Interferon for Treatment of Polycythemia Vera
AOP Orphan Pharmaceuticals AG reported the completion of recruitment for its Phase III trial PROUD-PV to support global licensure of Ropeginterferon alfa 2b, a novel, long-acting, mono-pegylated Interferon for the treatment of Polycythemia Vera. [AOP Orphan Pharmaceuticals AG] Press Release

From our sponsor:
View immunology lectures, protocols and other resources on the
Human Immunology Portal.
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
NEW 2015 World Stem Cell Summit (WSCS15)
December 10-12, 2015
Atlanta, United States

Visit our events page to see a complete list of events in the cord blood community.
NEW Research Scientist – Cell Signaling in Normal and Leukemic Hematopoietic Stem and Progenitor Cells (Indiana University)

NEW Manufacturing Manager – Cell Therapy (Opexa Therapeutics)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Scientist – Pluripotent Stem Cell Media Development, High Throughput Screening (STEMCELL Technologies Inc.)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Laboratory Technician – Stem Cell Storage (SLS Services Ltd)

Postdoctoral Fellows – Leukemia Research and Stem Cell Biology (Josep Carreras Leukemia Research Institute)

PhD Studentship – Stem Cells and Tissue Engineering (Queensland University of Technology)

Senior Process Development Engineer (Sangamo BioSciences, Inc.)

Director – Vector Production (Sangamo BioSciences, Inc.)

PhD Studentships – Expansion of Umbilical Cord Blood Stem Cells (University College London)

Cord Tissue Processing Technician (Cord Blood Registry)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or suggestions? Submit your feedback here
Learn more about Cord Blood News: Archives | Events | Contact Us